Annual report

Period2019-01-01 → 2019-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100IBOW.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥1.3bn2019-01-01 → 2019-12-31StandaloneNet sales
Revenue¥169m2018-01-01 → 2018-12-31StandaloneNet sales
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Operating income−¥511m2019-01-01 → 2019-12-31StandaloneOperating income
Operating income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOperating income
Ordinary income−¥539m2019-01-01 → 2019-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31StandaloneOrdinary income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥909m2019-01-01 → 2019-12-31StandaloneIncome before income taxes
Profit before tax−¥1.2bn2018-01-01 → 2018-12-31StandaloneIncome before income taxes
Net income−¥912m2019-01-01 → 2019-12-31StandaloneProfit loss
Net income−¥1.2bn2018-01-01 → 2018-12-31StandaloneProfit loss
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.4bnat 2019-12-31StandaloneAssets
Total assets¥3.4bnat 2018-12-31StandaloneAssets
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥926mat 2019-12-31StandaloneLiabilities
Total liabilities¥529mat 2018-12-31StandaloneLiabilities
Net assets / equity¥3.5bnat 2019-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.3bnat 2019-12-31StandaloneCash and deposits
Cash and deposits¥2.5bnat 2018-12-31StandaloneCash and deposits
Cash & equivalents¥3.1bnat 2019-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥238m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥4m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥342m2018-01-01 → 2018-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥240.71at 2019-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio78.7%at 2019-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued14,331,300at 2019-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees27at 2019-12-31StandaloneNumber of employees
Employees30at 2018-12-31StandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingdepreciation2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2019-12-31¥3.9bn
Reconciling Itemsreconcilingsegment profit2019-01-01 → 2019-12-31−¥733m
Diagnostic Divisionreportable segmentcapex2019-01-01 → 2019-12-31¥10m
Diagnostic Divisionreportable segmentdepreciation2019-01-01 → 2019-12-31¥303,000
Diagnostic Divisionreportable segmentemployeesat 2019-12-316 pure
Diagnostic Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentsegment assetsat 2019-12-31¥10m
Diagnostic Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31−¥152m
Pharmaceutical Divisionreportable segmentemployeesat 2019-12-317 pure
Pharmaceutical Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentsegment assetsat 2019-12-31¥420m
Pharmaceutical Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31¥373m
—segment totalemployeesat 2019-12-3113 pure
Total Of Reportable Segments And Otherssegment totalcapex2019-01-01 → 2019-12-31¥10m
Total Of Reportable Segments And Otherssegment totaldepreciation2019-01-01 → 2019-12-31¥303,000
Total Of Reportable Segments And Otherssegment totalrevenue2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2019-12-31¥430m
Total Of Reportable Segments And Otherssegment totalsegment profit2019-01-01 → 2019-12-31¥221m
Reconciling Itemsreconcilingdepreciation2018-01-01 → 2018-12-31¥2m
Reconciling Itemsreconcilingsegment profit2018-01-01 → 2018-12-31−¥593m
Diagnostic Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥16m
Diagnostic Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥170m
Pharmaceutical Divisionreportable segmentrevenue2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentrevenue external2018-01-01 → 2018-12-31¥153m
Pharmaceutical Divisionreportable segmentsegment profit2018-01-01 → 2018-12-31−¥485m
Total Of Reportable Segments And Otherssegment totalrevenue2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2018-01-01 → 2018-12-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2018-01-01 → 2018-12-31−¥654m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 897
ItemContextValueUnit
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember11481000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember1303844000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-JPY
Net salesCurrentYearDuration_NonConsolidatedMember1303844000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember373069000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember-151655000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember221414000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-732877000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-511463000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember420313000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember9933000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember430246000JPY
AssetsCurrentYearInstant_NonConsolidatedMember_ReconcilingItemsMember3949810000JPY
AssetsCurrentYearInstant_NonConsolidatedMember4380056000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember303000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember303000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember2806000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember3109000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember10237000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember10237000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember3290000JPY
Increase in property plant and equipment and intangible assetsCurrentYearDuration_NonConsolidatedMember13527000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書(2022年11月17日付け訂正報告書の添付インラインXBRL)
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2020-03-27
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第16期(自 2019年1月1日 至 2019年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  浦田 泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役管理担当  吉村 圭司
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役管理担当  吉村 圭司
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant-
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2018-12-31pass
balance sheet identitynon_consolidated 2019-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · operating cash flownon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · operating cash flownon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · revenuenon_consolidated 2018-01-01/2018-12-31pass
statement vs summary · revenuenon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · total assetsnon_consolidated 2018-12-31pass
statement vs summary · total assetsnon_consolidated 2019-12-31pass